Search results
Alkermes (ALKS) Gets Final Award in Janssen Arbitration, Ups View
Zacks via Yahoo Finance· 1 year agoAlkermes ALKS received a final award in its arbitration proceedings with Janssen Pharmaceuticals, a...
Alkermes (ALKS) Q2 Earnings & Revenues Beat Estimates
Zacks via Yahoo Finance· 11 months agoAlkermes (ALKS) reports encouraging second-quarter results, wherein both earnings and revenues beat...
Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation
Zacks via Yahoo Finance· 1 year agoBristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being...
Johnson & Johnson is ditching its script logo for all-new design after 136 years
KREX articles via Yahoo News· 9 months ago(AP) – Johnson & Johnson is signing off on a new logo. The health care giant said Thursday that it...
JnJ news: New Brunswick company dumps iconic script logo for 'new era'
App.com | Asbury Park Press via Yahoo Finance· 9 months agoNEW BRUNSWICK - Johnson & Johnson, the New Jersey health care giant with a storied history,...
Generative AI is top of mind for all types of leaders, from Treasury Secretary Janet Yellen to J&J...
Fortune via Yahoo Finance· 8 months agoThis week’s episode of Fortune‘s Leadership Next podcast features two conversations from the 2023...
Alkermes (ALKS) to Report Q2 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 11 months agoAlkermes ALKS is scheduled to report second-quarter 2023 results on Jul 26. Its earnings surprise...
MeiraGTx Holdings PLC Reports First Quarter 2024 Financial Results
GuruFocus.com via Yahoo Finance· 1 month agoRevenue: Reported at $0.7 million for Q1 2024, a significant decrease from $3.3 million in Q1 2023,...
Will Bristol Myers (BMY) Gain From New Drugs' Label Expansion?
Zacks via Yahoo Finance· 1 year agoBristol-Myers Squibb BMY has recently been enjoying a string of positive regulatory updates. The...
Medicare drug price negotiations unlikely to be derailed by lawsuits: UBS
Yahoo Finance via AOL· 10 months agoLawsuits brought by big pharmaceutical companies and industry lobbying groups are unlikely to delay...